Skyrizi (risankizumab-rzaa) is a prescription injection that’s used to treat certain autoimmune disorders, such as plaque psoriasis and Crohn’s disease. Skyrizi comes in a few different forms for ...

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...

Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body’s immune system and help to ...

Skyrizi (risankizumab-rzaa) and Humira (adalimumab) are prescription drugs that treat conditions such as psoriatic arthritis. The cost of both drugs depends on several factors. Skyrizi and Humira are ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Please provide your email address to receive an email when new articles are posted on . More patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs.

AbbVie ABBV announced the submission of regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its drug Skyrizi (risankizumab) for a new indication, moderately to ...

The approval was based on data from 2 pivotal phase 3 studies, which compared Skyrizi to placebo in adults with active PsA who had an inadequate response or were intolerant to biologic therapy and/or ...